The Net Profit of Sincerity Pharmaceutical in the First Half of the Year Increased by 47.03% Year on Year

A report from our correspondent (reporter wuyixuan) on the evening of August 26, Zhejiang sincerity Pharmaceutical Co., Ltd. (hereinafter referred to as "sincerity pharmaceutical") released its 2025 semi annual report. The company achieved an operating income of 417million yuan, an increase of 17.11% over the same period last year; The net profit attributable to shareholders of listed companies was 112million yuan, an increase of 47.03% over the same period last year; The net profit attributable to shareholders of listed companies after deducting non recurring profits and losses was 111million yuan, an increase of 54.21% over the same period last year.

This year, sincere pharmaceutical industry has adhered to responding to the call of the state to vigorously develop the marine economy, especially marine biomedicine, and to the "two wheel drive" of drugs and health products.

In the pharmaceutical field, sincerity pharmaceutical has always adhered to the foundation of "taking the varieties of the whole industry chain as the core", continued to increase R&D investment, and consolidated and improved its competitive advantages in the clinical treatment fields of bone and joint, cardio cerebrovascular, anti infection, nervous system, etc.

In the first half of this year, sincerity pharmaceutical, based on the principle of giving priority to advantageous and profitable varieties, focused and planned to promote the consistency evaluation and new product research and development. Citicoline sodium injection (two specifications) successfully passed the consistency evaluation; The new product thiopurine tablets were successfully approved, and dobutamine hydrochloride API was successfully filed. As of the disclosure date of the interim report, pramivir injection has been approved for drug registration.

In the field of big health products, the sincere pharmaceutical strategy focuses on the dual track of marine biomedicine and silver economy, seizing the opportunity of consumption upgrading and health awareness improvement, and striving to build it as the core growth engine of the company's future development.

Source: Securities Daily